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Abstract
Aims: Hepatic steatosis has been related to insulin resistance and increased diabetes risk. We assessed whether combination
of diabetes risk factors, evaluated by the Finnish Diabetes Risk Score, was associated with risk of hepatic steatosis in an
apparently healthy Chinese population.
Research Design and Methods: The study samples were from a community-based health examination survey in central
China. In total 1,780 men and women (18–64 y) were included in the final analyses. Hepatic steatosis was diagnosed by
ultrasonography. We created combination of diabetes risk factors score on basis of age, Body Mass Index, waist
circumference, physical activity at least 4 h a week, daily consumption of fruits, berries or vegetables, history of
antihypertensive drug treatment, history of high blood glucose. The total risk score is a simple sum of the individual
weights, and values range from 0 to 20.
Results: Hepatic steatosis was present 18% in the total population. In multivariate models, the odds ratios of hepatic
steatosis were 1.20 (95%CI 1.15–1.25) in men and 1.25 (95%CI 1.14–1.37) in women by each unit increase in the combination
of diabetes risk factors score, after adjustment for blood pressure, liver enzymes, plasma lipids, and fasting glucose. The area
under the receiver operating characteristic curve for hepatic steatosis was 0.78 (95%CI 0.76–0.80), 0.76 in men (95%CI 0.74–
0.78) and 0.83 (95%CI 0.79–0.87) in women.
Conclusions: Our data suggest that combination of major diabetes risk factors was significantly related to risk of hepatic
steatosis in Chinese adults.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common
chronic liver disease in the world [1–3], which comprises a wide
group of progressive alterations in liver structure and function,
ranging from hepatic steatosis and non-alcoholic steatohepatitis
(NASH) to fibrosis and cirrhosis [4].
In previous studies, it has been found that combination of
diabetes risk factors, such as the Finnish Diabetes Risk Score
(FINDRISC), was related to increased risk of hepatic steatosis [5].
However, these studies are mostly in the White population, and
data in Asians are lacking. The present study was to evaluate
whether combination of diabetes risk factors, evaluated as
FINDRISC, was associated with hepatic steatosis in a large
sample of Chinese adults.
Methods
1 Study Population
In the Cardiometabolic Risk in Chinese (CRC) Study, we
performed a community-based health examination survey for
6,431 individuals (18–93 y) who were randomly selected from
residents living in the urban area of Xuzhou, China, in 2009. All
subjects underwent a complete medical examination, a clinical
consultation, blood laboratory tests, and an ultrasonographic
abdominal scan. All individuals provided details of their demo-
graphic, medical history, and use of medication at the time of their
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clinical consultation. Individuals with missing data and those with
a previous history of liver disease, defined as a positive test for
hepatitis, history of cirrhosis, whose daily alcohol intake
was.=20 g, biliary disease, or diabetes mellitus were excluded
from the present analysis. In total, 1,780 men and women (18–
64 y) were included in the final analyses. There was not significant
difference in age and anthropometrics between individuals who
were included and those who were not included in the analyses.
The protocol and informed consent document were approved by
the ethics committee of the Central Hospital of Xuzhou, China.
All patients gave written informed consent. Hepatic steatosis was
diagnosed by ultrasonography using an abdominal probe at 2–
5 MHz. Longitudinal, subcostal, ascending, and oblique scans
were performed.
2 Anthropometric measures
Body weight was measured in light clothing to the nearest
0.1 kg and height to the nearest 0.5 cm. Height and body weight
were measured with participants standing without shoes and heavy
outer garments. Waist circumference was measured at the
minimum abdominal girth to the nearest 0.1 cm. Body Mass
Index(BMI) was calculated as weight (in kilograms) divided by
height (in meters) squared. Blood pressure (BP) was measured after
the subject had rested for at least 5 minutes with a mercury
manometer by doctors. Three measurements, 60 seconds apart,
were taken. The mean of the three measurements was used for
analysis.
3 Assessment of biomarkers
Venous blood sample was drawn from all subjects after an
overnight fast (10 h). The blood was transferred into glass tubes
and allowed to clot at room temperature. Immediately following
clotting serum was separated by centrifugation for 15 min at
3,000 rpm. Participants also underwent a 75-g oral glucose
tolerance test (OGTT). The OGTT was carried out according
to World Health Organization (WHO) recommendations. Blood
samples were drawn at 120 minutes after the glucose or
carbohydrate load. Plasma glucose was measured using the
hexokinase glucose-6-phosphate dehydrogenase method (Type
7600; Hitachi Ltd, Tokyo, Japan). The levels of total cholesterol,
triglyceride, high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C), aspartate aminotransfer-
ase(AST), Alanine aminotransferase(ALT), alkaline phosphatase,
and gamma glutamyl transpeptidase (cGT) were determined
enzymatically using an autoanalyzer (Type 7600; Hitachi Ltd.,
Tokyo, Japan). Fasting insulin was measured by a radioimmuno-
assay ethod (Pharmacia, Uppsala, Sweden). HbA1c was measured
using high performance liquid chromatography (HPLC; HLC-
723G7 hemoglobin HPLC ana-lyzer, Tosoh Corp.) according to
the standardized method.
4 Combination of diabetes risk factors
As previously described [6], The FINDRISC contains seven
questions, with categorized answers, about age, BMI, waist
circumference, physical activity at least 4 h a week, daily
consumption of fruits, berries or vegetables, history of antihyper-
tensive drug treatment, history of high blood glucose. The total
risk score is a simple sum of the individual weights, and values
range from 0 to 20. The questionnaire was applied by registered
nutritionists at the time of the routine diet interview of the health
evaluation protocol.
5 Statistical analyses
Statistical analyses were performed by Statistical Package for
Social Science (SPSS) version 13.0. Continuous variables were
expressed in mean 6 standard deviation. Two-sided t-tests and
chi-square tests were used to analyze the differences between the
groups at baseline. Student’s t-test and one-way analysis of
variance (ANOVA) were used to compare continuous variables.
The relations between FINDRISC levels and hepatic steatosis
were examined using logistic regression models, adjusting for
covariates including BP, AST, ALT, gamma GT, total cholesterol,
HDL cholesterol, fasting glucose. Odds ratios with 95%
confidence intervals for the FINDRISC per unit increase for
prediction of steatosis were performed by logistic regression. All
reported P values are two tailed. The level of statistical significance
was set to 0.05.
Results
Among the 1780 participants, there were 932 (52.4%) men and
848 (47.6%) women. The baseline characteristics of the study
population are presented in Table 1. Compared to women, men
had a higher BMI, waist circumference, blood pressure, fasting
plasma glucose, 2 h Plasma glucose, total serum cholesterol, LDL-
C, and triglyceride (P values,0.001), whereas women had a
higher mean HDL-C level compared with men. The mean
FINDRISC was 8 in men and 6 in women. The prevalence of
hepatic steatosis in this study population was 18.6%. There was no
statistically significant difference between men and women, 19.5%
in men, 17.4% in women.
The performance of combination of diabetes risk factors in
predicting hepatic steatosis using receiver operating characteristic
curve(ROC) analysis is presented in Figure 1. The area under the
Table 1. Clinical characteristics of the participants by gender.
Female Male Total
N 848 1630 2478
Age (years) 44.467.8 46.469.3 45.768.8
BMI (kg/m2) 23.063.0 25.362.9 24.563.2
Waist circumference (cm) 78.368.1 89.868.2 85.969.8
Systolic blood pressure (mmHg) 116.1614.9 126.4615.4 122.9616.0
Diastolic blood pressure (mmHg) 74.8610.1 81.8611.2 79.4611.3
Fasting plasma glucose (mmol/L) 4.960.6 5.461.3 5.261.1
2 h Plasma glucose (mmol/L) 6.761.8 7.563.1 7.262.8
Fasting serum insulin (mmol/L) 8.364.6 9.867.0 9.366.3
Total cholesterol (mmol/L) 5.060.8 5.260.9 5.160.9
Serum Triglycerides (mmol/L) 1.160.8 2.061.8 1.761.6
Serum HDL cholesterol (mmol/L) 1.460.3 1.260.3 1.360.3
Serum LDL cholesterol (mmol/L) 2.960.7 3.060.8 3.060.8
Aspartate aminotransferase (mmol/L) 16.0612.1 26.5619.0 22.9617.7
Alanine aminotransferase (mmol/L) 15.865.9 19.368.9 18.168.2
Alkaline phosphatase (mmol/L) 51.3616.0 59.5615.8 56.7616.3
Gamma glutamyl transpeptidase
(mmol/L)
17.2618.3 39.0640.1 31.6636.3
FINDRISC 6.163.3 7.563.6 7.063.5
The prevalence of steatosis(n/N) 149/848 182/932 331/1780
Data are means 6 standard deviations for the continuous variables and
percentage for the categorical variables.
doi:10.1371/journal.pone.0090101.t001
Diabetes Risk Factors and Hepatic Steatosis
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ROC curve for steatosis was 0.78 (95% CI 0.76–0.80), 0.76 in men
(95% CI 0.74–0.78) and 0.83(95% CI 0.79–0.87) in women after
adjustment for blood pressure, liver enzymes, plasma lipids, and
fasting glucose. For cut point of FINDRISC .=8, sensitivity was
0.70 and specificity was 0.72.
All the risk factors for cardiovascular disease had a strong direct
association with the FINDRISC values(Table 2). Liver enzymes,
such as aspartate aminotransferase, alanine aminotransferase,
alkaline phosphatase and gamma glutamyl transpeptidase escalat-
ed with the increasing value of the risk score. In both men and
women, there was a marked increase in the prevalence of steatosis
with increasing value of the risk score. In men, the proportion of
subjects who were classified as having the steatosis from 2% in the
lowest risk score category to 62.1% in the highest. In women, the
corresponding numbers were 1% and 58%.
Table 3 shows the association of the FINDRISC as a
continuous variable with the presence of steatosis. In the
unadjusted model each unit increase in the FINDRISC question-
naire increased the odds ratios of steatosis by 1.33 in men and 1.45
in women. This association remained robust even after adjustment
for blood pressure, liver enzymes, plasma lipids, and fasting
glucose, and the odds ratios were 1.20 in men and 1.25 in women.
Model 1: FINDRISC only; Model 2: model 1 + SBP + DBP;
Model 3: model 1 + AST, ALT, cGT; Model 4: model 1 + TC +
HDL-C; Model 5: model 1 + FBG; Model 6: model 1 + SBP +
DBP+ AST+ALT+cGT+ TC+ HDL-C + FBG.
Discussion
In the present study of a large sample of Chinese adults, we
found that combination of diabetes risk factors, evaluated as the
FINDRISC, was associated with increased risk of hepatic steatosis.
The associations were consistent in men and women even after
adjustment for blood pressure, liver enzymes, plasma lipids, and
fasting glucose.
The prevalence of hepatic steatosis in this study population was
18.6%, 19.5% in men, 17.6% in women, which was lower than
previous reports in other parts of the world (20–30% in Europe
and the Middle East [7–9], 20–30% in North America and similar
countries [10,11]). Differences may relate to ethnicity and lifestyle,
with the majority of our study subjects having lower proportion of
men in our study (52.4%) than in Carvalho’s study (80.8%).
NAFLD was more frequent in men [12].
Finding effective approaches to prevent NAFLD is a critical
public health priority. Given the recent clinical trials showing that
prevention of NAFLD with lifestyle intervention is possible, there
is also increasing interest in the development of tools to identify
high-risk individuals who might benefit from interventions, or
persons worth further testing for such as ultrasonography or liver
biopsy. Given the expense, inconvenience, limitations, and risks
associated with a liver biopsy, it is unsuitable for the screening of
the general population for such a prevalent condition.
Several modalities have been used to diagnose NAFLD non-
invasively with variable sensitivity and specificity, including
ultrasonography, computed tomography (CT), magnetic reso-
nance imaging (MRI), and MRS. Ultrasound is the most readily
available imaging modality for the diagnosis of fatty liver.
Ultrasound findings of NAFLD include hepatomegaly, diffuse
increased echogenicity of the liver parenchyma, blurring of
intrahepatic vessels, and loss of echoes of the posterior hepatic
segments. A review of studies comparing the role of ultrasound in
diagnosing histologically proven NAFLD reported an overall
sensitivity and specificity for the detection of moderate to severe
steatosis (.=20–30% steatosis) of 84% and 93%, respectively,
with an accuracy of 0.93 [13]. Ultrasound sensitivity varies
considerably with liver fat content and to technical limitations in
morbidly obese patients. In a recent meta-analysis of the
performance of different imaging modalities in diagnosing
biopsy-proven NAFLD, CT was equivalent if not inferior to
ultrasound [14]. In addition, CT carries the disadvantage of
radiation exposure. Magnetic resonance imaging and MRS
perform better than ultrasound or CT, particularly in detecting
lower degrees of steatosis. However, they are costly and not widely
available.
The presence of NAFLD is correlated with the degree of
peripheral and hepatic IR [15,16]. Ultrasound-diagnosed NAFLD
increased the risk of diabetes 2.5-fold [17]. The reverse is also true,
with increases in fasting blood glucose and insulin levels leading to
a higher overall prevalence of NAFLD, which is estimated to be
63–69% in patients with diabetes [18–20].
Since there is a close association of obesity, insulin resistance,
and type 2 diabetes with NAFLD, we assessed whether combina-
tion of diabetes risk factors, evaluated as FINDRISC, was
associated with hepatic steatosis in a large sample of Chinese
adults. Risk factors for type 2 diabetes seem to differ between
ethnic groups. Consistent in all of them, a family history of
diabetes confers an increased risk of developing type 2 diabetes,
but its relative effect decreases with increasing prevalence of type 2
diabetes in the population. Low level of physical activity has been
associated with risk of diabetes. The incidence of type 2 diabetes in
individuals with impaired glucose tolerance can be reduced
through diet and exercise [21]. Other risk factors, like abdominal
obesity, hypertension confers an increased risk of type 2 diabetes
[22,23].
Figure 1. Receiver operating characteristic curve for the
performance of steatosis in the study population. The analyses
were adjusted for blood pressure, liver enzymes, plasma lipids, and
fasting glucose.
doi:10.1371/journal.pone.0090101.g001
Diabetes Risk Factors and Hepatic Steatosis
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Several previous studies have shown that FINDRISC was
related to type 2 diabetes, the metabolic syndrome, insulin
resistance [6,24,25]. In a recent cross-sectional study including
821 Brazil non-diabetic subjects without previous hepatic disease,
it was found that the FINDRISC could be a useful primary
screening tool for the presence of steatosis [5]. In that study the
ROC curve for the undiagnosed prevalent diabetes was 0.80, 0.80
in men and 0.83 in women, which was consistent with the present
findings.
In this study, we found that combination of diabetes risk factors,
evaluated by the FINDRISC, was associated with risk of hepatic
steatosis in an apparently healthy Chinese population. The area
under the ROC curve was 0.78. For cut point of the sum of
combination of diabetes risk factors score$8, sensitivity is 0.70 and
specificity is 0.72. In addition, the score was shown to be closely
associated with various CVD risk factors. BMI and waist
circumference performed worse than the FINDRISC in predicting
steatosis in our study. FINDRISC can be applied by primary
health care physicians and other health care professionals without
the need of laboratory and/or imaging tests. Identified high-risk
individuals should be evaluated by special tests. Also FINDRISC
predicts not only steatosis but also type 2 diabetes, abnormal
glucose tolerance, the metabolic syndrome [6,12,24,25].
However, several limitations of this study warrant consideration.
Firstly, in our study, we did not collection information of
Quantitative alcoholic consumption and smoking. For example,
Table 2. Cardiovascular risk factor profile by gender and FINDRISC values.
FINDRISC value
Men
0–3 4–6 7–10 11–14 15–20 P value
Age (years) 39.4 44.9 47.6 51.2 55.3 ,0.001
BMI (kg/m2) 22.6 24.4 25.7 27.6 29.2 ,0.001
Waist circumference (cm) 82.5 86.5 91.5 96.7 100.0 ,0.001
Systolic blood pressure (mmHg) 114.8 120.3 129.0 138.4 143.4 ,0.001
Diastolic blood pressure (mmHg) 73.3 78.0 83.7 90.3 91.3 ,0.001
Fasting plasma glucose (mmol/L) 4.9 5.1 5.3 5.9 7.5 ,0.001
2 h Plasma glucose (mmol/L) 6.1 6.7 7.7 8.8 12.6 ,0.001
Fasting serum insulin (mmol/L) 6.9 8.4 10.2 12.2 18.2 ,0.001
Total cholesterol (mmol/L) 4.8 5.0 5.3 5.4 5.5 0.020
Serum Triglycerides (mmol/L) 1.2 1.7 2.1 2.5 3.1 ,0.001
Serum HDL cholesterol (mmol/L) 1.2 1.2 1.2 1.1 1.1 ,0.001
Serum LDL cholesterol (mmol/L) 2.9 3.0 3.1 3.1 3.0 ,0.001
Aspartate aminotransferase (mmol/L) 19.9 25.0 28.2 30.3 31.3 ,0.001
Alanine aminotransferase (mmol/L) 16.7 18.7 20.3 20.4 21.7 ,0.001
Alkaline phosphatase (mmol/L) 57.5 59.6 59.6 59.4 66.3 ,0.001
Gamma glutamyl transpeptidase (mmol/L) 25.0 35.7 42.6 47.6 53.1 ,0.001
The prevalence of steatosis (n/N) 2/100 24/260 66/320 72/223 18/29 ,0.001
women
Age (years) 38.8 44.7 46.2 53.8 59.7 ,0.001
BMI (kg/m2) 20.9 22.0 24.4 26.9 29.9 ,0.001
Waist circumference (cm) 72.4 75.5 82.7 89.2 95.0 ,0.001
Systolic blood pressure (mmHg) 108.7 111.9 120.4 134.1 149.7 ,0.001
Diastolic blood pressure (mmHg) 70.1 72.3 77.9 85.5 90.0 ,0.001
Fasting plasma glucose (mmol/L) 4.7 4.9 5.1 5.3 6.2 ,0.001
2 h Plasma glucose (mmol/L) 6.1 6.5 7.0 7.7 9.7 ,0.001
Fasting serum insulin (mmol/L) 7.3 7.1 9.2 12.0 13.6 ,0.001
Total cholesterol (mmol/L) 4.7 5.0 5.1 5.3 5.6 ,0.001
Serum Triglycerides (mmol/L) 0.8 1.0 1.3 1.6 1.7 ,0.001
Serum HDL cholesterol (mmol/L) 1.5 1.4 1.3 1.3 1.2 ,0.001
Serum LDL cholesterol (mmol/L) 2.6 2.8 3.1 3.2 3.5 0.023
Aspartate aminotransferase (mmol/L) 14.3 14.9 17.5 19.6 20.5 0.001
Alanine aminotransferase (mmol/L) 15.2 15.1 16.3 17.6 17.8 0.003
Gamma glutamyl transpeptidase (mmol/L) 14.9 15.1 19.9 21.2 25.5 0.001
The prevalence of steatosis (n/N) 3/245 24/249 46/270 24/72 7/12 ,0.001
Data are means except where noted otherwise.
doi:10.1371/journal.pone.0090101.t002
Diabetes Risk Factors and Hepatic Steatosis
PLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e90101
failure to adjust for smoking may lead to over-estimation of
relationship between FINDRISC and liver steatosis. Cigarette
smoking has been consistently related to T2DM risk [26]. If
smoking are adjusted, the resulting OR and ROC values tend to
be lower. Secondly, ultrasound could have under-estimated the
already high prevalence of steatosis in our population. Several
studies have shown that ultrasound for detecting hepatic steatosis
has a sensitivity of 60% to 94%, and a specificity of 84% to 95%.
Its sensitivity is reduced in the morbidly obese, and its
performance is highly operator-dependent. The prevalence of
liver steatosis among Chinese population is 20.09% [27], while the
prevalence of hepatic steatosis in this study population was 18.6%.
Lastly, the study was performed in a Chinese population. Further
studies in other populations of different ethnicities are warranted
to verify our findings.
In summary, in the present study of Chinese adults, combina-
tion of diabetes risk factors was associated with hepatic steatosis,
and it also could be a useful primary screening tool for the
presence of steatosis.
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